Chris Gibson (Photo By Vaughn Ridley/Sportsfile for Web Summit via Getty Images)
April 17, 2021 12:59 PM EDTUpdated April 23, 11:58 AM
Bioregnum
Opinion

Re­cur­sion founders gin for­tunes as IPO back­ers show­er $436M on one of the biggest boasts in AI — based on some very small deals

In the AI drug de­vel­op­ment world, boast­ing of­ten comes with the ter­ri­to­ry. Yet few can ri­val Re­cur­sion when it comes to claim­ing the lead role …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times